What is the Genentech Endowment for Cystic Fibrosis?

The Genentech Endowment for Cystic Fibrosis is an independent, non-profit endowment dedicated to expanding access to Pulmozyme® (dornase alpha) therapy to qualifying uninsured and underinsured CF patients. The Endowment was established by Genentech, manufacturers of Pulmozyme®, in 1993. The Endowment is fully funded by Genentech and operated through an independent Board of Directors.

What programs does the Endowment offer?

The Endowment offers three programs designed to meet the special needs of the CF population.

• If you are uninsured, the Endowment offers an Uninsured Patient Program. You may also be eligible for this program if you have insurance coverage but the policy has certain coverage limitations, such as no prescription drug benefit.



• If you have insurance, you may qualify for assistance through the Copayment Assistance Program. This program assists qualifying patients with Pulmozyme® out-of-pocket copayment requirements based upon a sliding scale adjusted for income, family size and other pre-established criteria.



• Both uninsured and underinsured patients may benefit from the Premium Assistance Program. This program assists qualifying patients with health insurance premium costs. Assistance levels are based upon a sliding scale.